Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mapatumumab - Human Genome Sciences

Drug Profile

Mapatumumab - Human Genome Sciences

Alternative Names: Death-receptor-4-monoclonal-antibody; DR4 mAB; DR4-monoclonal-antibody; HGS-1012; HGS-ETR1; TRAIL-R1 monoclonal antibody; TRAIL-receptor-1-monoclonal-antibody; TRM-1

Latest Information Update: 28 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Human Genome Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; TNF related apoptosis inducing ligand stimulants; TRAIL receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cervical cancer
  • Suspended Liver cancer
  • No development reported Colorectal cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 29 Nov 2017 Human Genome Sciences completes a phase II trial for Liver cancer (First-line therapy, Combination therapy, Late-stage disease) in USA, Germany, Poland, Puerto Rico, Romania, Russia and Ukraine (IV) (NCT01258608)
  • 10 Sep 2015 Phase-I/II development for Cervical cancer is ongoing in Netherlands
  • 10 Sep 2015 No recent reports on development identified - Phase-II for Multiple myeloma (Combination therapy) in USA, Canada, Australia and India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top